Ambler, PA, United States of America

Oren Gilad

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Oren Gilad: Innovator in Cancer Treatment

Introduction

Oren Gilad is a prominent inventor based in Ambler, PA (US), known for his significant contributions to the field of cancer treatment. With a total of 4 patents to his name, he has made strides in developing innovative therapies that target critical pathways in cancer biology.

Latest Patents

Among his latest patents are the Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use. This disclosure focuses on compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase, along with methods for their application. Additionally, he has developed macrocyclic compounds that serve as ATR protein kinase inhibitors, which include pharmaceutically acceptable salts. These compounds are designed to be part of pharmaceutical compositions aimed at treating cancer in patients.

Career Highlights

Oren Gilad is currently associated with Atrin Pharmaceuticals LLC, where he continues to advance his research and development efforts. His work is pivotal in the ongoing quest for effective cancer therapies, showcasing his commitment to improving patient outcomes through innovative solutions.

Collaborations

He collaborates with notable colleagues, including Henry Joseph Breslin and Gerhard Sperl, to further enhance the impact of his research in the pharmaceutical industry.

Conclusion

Oren Gilad's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a key figure in the field. His work continues to inspire advancements in therapeutic strategies for cancer patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…